

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) A fusion polypeptide conjugate comprising a first and second polypeptide, the two polypeptides having an affinity with respect to each other, wherein the first one polypeptide is being a cytokine of the interleukin-6 family receptor, or subunit thereof, and the second other polypeptide is a being-a cytokine, or subunit thereof, that binds to said cytokine receptor that binds to the first polypeptide, wherein the first and second polypeptides are linked to each other via a polypeptide linker.

Claim 2. (Currently Amended) The fusion polypeptide conjugate according to claim 1, wherein the receptor is a subunit of a cytokine receptor and binds to a ligand.

Claim 3. (Currently Amended) The fusion polypeptide conjugate according to claim 1, wherein the cytokine is a subunit of a cytokine and binds to said receptor.

Claim 4. (Currently Amended) The fusion polypeptide conjugate according to claim 1, wherein the ~~cytokine~~ receptor is an IL-6 receptor and the cytokine is an IL-6.

Claim 5. (Withdrawn) The conjugate according to claim 1, wherein the cytokine receptor is a CNTF receptor and the cytokine is a CNTF.

Claim 6. (Canceled)

Claim 7. (Currently Amended) DNA coding for the fusion polypeptide conjugate according to claim 1.

Claim 8. (Previously Presented) An expression plasmid comprising the DNA according to claim 7.

Claim 9. (Previously Presented) A transformant containing the expression plasmid according to claim 8.

Claim 10. (Canceled)

Claim 11. (Canceled)

Claim 12. (Canceled)

Claim 13. (New) The fusion polypeptide of claim 1, wherein the receptor is an IL-11 receptor and the cytokine is IL-11.

Claim 14. (New) A pharmaceutical composition comprising the fusion polypeptide of claim 1 or the DNA of claim 7, and a pharmaceutically acceptable carrier.